文献速递衰弱、肌少症与跌倒认知障碍与谵妄

血浆p-tau181阴性老年人的5年认知稳定性:MAPT研究分析

Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

该研究为多领域阿尔茨海默病预防试验(MAPT)的5年分析,纳入503名社区居住且血浆p-tau181数据可用的老年人,按3种切值判定p-tau阴性状态,用4项认知测验Z评分合成的认知复合分评估认知变化。结果显示,无论采用哪种切值,p-tau181阴性组整体在随访期间均未出现认知下降;在p-tau阴性人群中,出现认知下降者衰弱患病率高于未下降者。

要点

  • 血浆p-tau181阴性老年人5年内整体认知保持稳定。
  • p-tau阴性人群中认知下降者衰弱比例更高。
  • 若无脑病理生物标志物阳性或衰弱,单纯高龄未必伴认知下降。

核心结论

  • 血浆p-tau181阴性的社区老年人在5年随访中认知表现保持稳定。
  • 在p-tau181阴性人群中,发生认知下降者衰弱患病率高于未下降者。
  • 作者提出,缺乏脑病理生物标志物阳性或衰弱时,单纯高龄可能与认知下降无关。

研究设计与样本

  • 本研究为多领域阿尔茨海默病预防试验(MAPT)的5年分析。
  • 纳入503名社区居住且血浆p-tau181数据可用的老年人。
  • 采用线性混合模型比较不同血浆p-tau181状态下认知复合评分自基线的纵向变化。

主要发现

  • 研究结束时人群中位年龄为79岁(四分位距76-82)。
  • 无论采用哪种切值,p-tau181阴性组整体在随访期间均未出现认知下降。
  • p-tau181阴性组中认知下降者的衰弱患病率高于未下降者。

关键数值与推荐

  • p-tau阴性状态按3种切值判定:淀粉样蛋白PET阳性切值9.6 pg/mL。
  • p-tau阴性状态按基线p-tau181分布最高三分位切值10.9 pg/mL判定。
  • p-tau阴性状态按阿尔茨海默病诊断预测切值12.4 pg/mL判定。
  • 认知采用由4项认知测验Z评分衍生的经验证认知复合评分测量。

临床怎么用

  • 对血浆p-tau181阴性的老年人,可将其认知预后总体视为较稳定。
  • 在p-tau181阴性老年人中仍应评估衰弱,以识别认知下降风险较高者。
  • 解读p-tau181阴性结果时需结合衰弱状态,而非仅凭年龄判断认知风险。

局限性

  • 摘要未报告研究设计类型、随访失访及混杂调整等细节。
  • 3种p-tau阴性切值并存,结果解释需注意切值定义差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to assess the evolution of cognitive performances over a 5-year follow-up period in community-dwelling older people with negative plasma p-tau181 levels and to determine whether frailty could discriminate between those who experience cognitive decline and those who do not, in the p-tau negative groups. METHODS: This is a 5-year analysis of the Multidomain Alzheimer Prevention Trial (MAPT) testing cognitive evolution among 503 community-dwelling individuals with available data on plasma p-tau181. Negative p-tau status was assigned according to 3 different cut-offs: amyloid-PET positivity (9.6 pg/mL), highest tertile for baseline p-tau181 distribution (10.9 pg/mL), and Alzheimer's disease diagnosis prediction (12.4 pg/mL) cut-offs. Cognition was measured using a validated composite cognitive score derived from the Z-scores of 4 cognitive tests. Longitudinal changes from baseline in the composite cognitive score according to plasma p-tau181 status were compared using linear mixed models. RESULTS: In a population with an end-of-study median age of 79 years (interquartile range: 76-82), whatever the cut-off, the overall group with negative p-tau181 status did not develop cognitive decline over the follow-up. Among the p-tau181 negative groups, individuals who declined had a higher prevalence of frailty compared to those who did not decline. CONCLUSIONS: Cognitive performance in older people with negative plasma p-tau181 levels remains stable over a 5-year period. This may suggest that older age alone, in the absence of positive biomarkers for brain pathology (or frailty), is not associated with cognitive decline. Frailty may increase vulnerability to the neuropathological burden associated with Alzheimer's disease.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Bellelli F, Barreto PS, Cantet C, et al. Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study. J Gerontol A Biol Sci Med Sci. 2025. PMID: 40383731. doi:10.1093/gerona/glaf113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。